PRINCETON, N.J., June 2, 2025 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a late-stage immunotherapy company, announced the publication of three Versamune® HPV abstracts on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. These abstracts detail studies involving PDS Biotech's Versamune® HPV (PDS0101) and were presented during the Head and Neck Cancer Poster Session in Chicago, Illinois. The company's ongoing research is focused on HPV16-positive head and neck squamous cell carcinoma (HNSCC), a rapidly growing and significant medical concern. The VERSATILE-003 Phase 3 clinical trial is currently the only registrational trial exclusively targeting first-line recurrent/metastatic HPV16-positive HNSCC. This trial aims to evaluate the effectiveness of an HPV16-targeted T cell immunotherapy. The median overall survival data for this patient population remains durable at 30.0 months, following an additional 4.5 months of follow-up beyond the initial abstract.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.